Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

This study is tracking nerve damage (peripheral neuropathy) in children with leukemia who are receiving a chemotherapy drug called vincristine. Researchers want to understand when it starts, how bad it gets, and what factors predict which children will be most affected — so that future care can be better tailored. **You may be eligible if...** - Your child has been diagnosed with acute lymphoblastic leukemia (ALL) - Your child is between 8 and 17 years old - Your child will receive vincristine as part of the CCCG-ALL-2020 treatment protocol - Your child is alert and able to communicate their physical and emotional state - Both the child and parent have provided written consent to participate **You may NOT be eligible if...** - Your child is enrolled in another trial that uses electrical stimulation or exercise therapy for nerve-related symptoms - Your child has severe complications involving the heart, brain, or lungs - Your child had nerve problems from another condition before starting treatment (e.g., spinal cord injury, genetic disease) - Your child has a neuromuscular condition like cerebral palsy or traumatic brain injury - Your child has brain or spinal cancer, or needs multiple treatments including radiation Talk to your doctor to see if this trial is right for you.